
MSF responds to groundbreaking news that Johnson & Johnson will not enforce patents on key TB drug bedaquiline in low- and middle-income countries
30 September 2023, Geneva Christophe Perrin, TB Advocacy Pharmacist, MSF Access Campaign: “We welcome Johnson & Johnson’s (J&J) announcement finally paving the way for unfettered access to affordable generic versions of bedaquiline for all people living with